We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
The current 1VRTX market cap is 97.35B. The company's latest EPS is USD 13.8641 and P/E is 28.61.
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 4.16B | 6.21B | 7.58B | 8.99B | 9.92B |
| Operating Income | 1.2B | 2.86B | 2.78B | 4.31B | 3.83B |
| Net Income | 1.18B | 2.71B | 2.34B | 3.32B | 3.57B |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 8.32B | 11.75B | 13.43B | 18.15B | 22.73B |
| Total Liabilities | 2.23B | 3.06B | 3.33B | 4.24B | 5.15B |
| Total Equity | 6.09B | 8.69B | 10.1B | 13.91B | 17.58B |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | 1.57B | 3.25B | 2.64B | 4.13B | 3.54B |
| Investing | -1.24B | 99.39M | -340.9M | -321.1M | -3.14B |
| Financing | 126.77M | -505.28M | -1.48B | -67.7M | -562.2M |
| Market Cap | 97.35B |
| Price to Earnings Ratio | 28.61 |
| Price to Sales Ratio | 10.3 |
| Price to Cash Ratio | 9.85 |
| Price to Book Ratio | 5.81 |
| Dividend Yield | - |
| Shares Outstanding | 257.53M |
| Average Volume (1 week) | 20 |
| Average Volume (1 Month) | 16 |
| 52 Week Change | 1.65% |
| 52 Week High | 486.10 |
| 52 Week Low | 363.20 |
| Spread (Intraday) | 17 (4.5%) |
| Company Name | Vertex Pharmac Dl 01 |
| Address |
50 northern avenue boston, massachusetts 02210 |
| Website | https://www.vrtx.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
